Concerta vs Vyvanse
MEDICATION COMPARISON · FROM FDA LABELS AND HEAD-TO-HEAD STUDIES
Reviewed by Tariq Halim, MD · Last medical review: October 29, 2026 · Editorial policy
Side-by-side facts (from each FDA label)
Each cell is copied from that product’s key facts, which cite its current FDA prescribing information. Durations and doses come from each product’s own label studies; they are not a head-to-head comparison.
| Concerta | Vyvanse | |
|---|---|---|
| Drug class | CNS Stimulant · Methylphenidates | CNS Stimulant · Amphetamines |
| Active ingredient | methylphenidate hydrochloride | lisdexamfetamine dimesylate |
| FDA-approved ages | 6 to 65 years (FDA label) | ADHD: 6 years and older; BED: adults |
| Form and strengths | Extended-release tablet (OROS); 18 mg, 27 mg, 36 mg, 54 mg tablets (72 mg doses use a combination of tablets) | Capsule; chewable tablet; Capsules: 10, 20, 30, 40, 50, 60, 70 mg Chewable tablets: 10, 20, 30, 40, 50, 60 mg |
| Usual dose and maximum (label) | New to methylphenidate: start 18 mg once daily (adults 18 or 36 mg); maximum 54 mg/day (ages 6–12) or 72 mg/day (13–65). | Start 30 mg once daily in the morning; maximum 70 mg/day. |
| Duration (label) | About 10–12 hours after a morning dose; benefit lasted through 12 hours in the label’s studies in children. | Benefit through 12–13 hours in children and up to 14 hours in adults in label studies. |
| DEA schedule | Schedule II controlled substance (CII) | Schedule II controlled substance (CII) |
| Generic | Generic available (see Generic manufacturers) | Generic available (see Generic manufacturers) |
| Label date | Prescribing Information revised 04/2026 (DailyMed) | Prescribing Information revised 04/2026 (DailyMed) |
| Availability (site status, Oct 2026) | ER tablet shortage · brand available | FDA shortage listed · brand available |
Main differences in plain words
- Concerta contains methylphenidate hydrochloride; Vyvanse contains lisdexamfetamine dimesylate.
- Form: Concerta: extended-release tablet (OROS); Vyvanse: capsule or chewable tablet.
- Controlled status: both: Schedule II controlled substance (CII).
- Generic: Concerta: Generic available; Vyvanse: Generic available.
What studies compare them
The studies below include at least one direct (head-to-head) comparison of Concerta and Vyvanse or their active formulations. Only head-to-head trials, analyses of them and network meta-analyses are used for comparisons on this page; read the note under each study for what it can and cannot show.
-
Lisdexamfetamine vs OROS methylphenidate (adolescents)
In two adolescent trials comparing lisdexamfetamine and OROS methylphenidate directly, lisdexamfetamine was better in the fixed-dose trial but not in the flexible-dose trial.
Direct comparison in adolescents of lisdexamfetamine (Vyvanse) and OROS methylphenidate (the Concerta type).
Two 8-week RCTs (13–17 y). Forced-dose: LDX vs OROS-MPH −3.4 (p=0.0013; ES −0.33); flexible-dose: −2.1 (p=0.0717; ES −0.20). CGI-I improved: 81.4% vs 71.3% (forced, p=0.0188); 83.1% vs 81.0% (flexible, NS).
Funding / affiliation: Funded by Shire Development LLC (lisdexamfetamine manufacturer) per PubMed record.
Newcorn JH, Nagy P, Childress AC, et al. (2017). Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs 31(11):999-1014. DOI · PubMed 28980198
-
Lisdexamfetamine vs OROS methylphenidate
A later analysis of that same European trial found lisdexamfetamine reduced symptoms more than OROS methylphenidate (the Concerta-type formulation). This was a post hoc comparison the trial was not designed for.
Post hoc comparison of the two active arms of the trial below; the trial was not designed to compare them.
Post hoc analysis of Coghill 2013 (336 randomised; 317 full analysis set). ADHD-RS-IV LS mean change: LDX −24.3, OROS-MPH −18.7, placebo −5.7; LDX vs OROS −5.6 (−8.4 to −2.7; p<0.001). CGI-I improved difference 17.4% (NNT 6).
Soutullo C, Banaschewski T, Lecendreux M, et al. (2013). A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 27(9):743-51. DOI · PubMed 23801529
-
Lisdexamfetamine vs placebo (OROS-MPH reference arm)
In a 7-week European trial of 336 children and teens, lisdexamfetamine reduced symptoms much more than placebo. Concerta-type OROS methylphenidate, included as a reference, also beat placebo.
OROS methylphenidate was a reference arm; the trial was not powered to compare it with lisdexamfetamine.
Phase 3 RCT, n=336 (6–17 y), dose-optimised LDX 30–70 mg, OROS-MPH 18–54 mg, placebo. ADHD-RS-IV difference vs placebo: LDX −18.6 (−21.5 to −15.7; ES 1.80); OROS-MPH −13.0 (−15.9 to −10.2; ES 1.26). CGI-I improved: 78%, 61%, 14%. Not powered for LDX vs OROS comparison.
Coghill D, Banaschewski T, Lecendreux M, et al. (2013). European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 23(10):1208-18. DOI · PubMed 23332456
-
ADHD medicines in children (class)
An industry-funded network analysis of 36 trials ranked placebo-adjusted symptom improvement as largest for lisdexamfetamine, then extended-release methylphenidate, then guanfacine ER, then atomoxetine. These are indirect comparisons.
Indirect (network) comparison funded by the lisdexamfetamine manufacturer; not a head-to-head trial.
Bayesian NMA of 36 RCTs (6–17 y). ADHD-RS-IV change vs placebo: lisdexamfetamine −14.98 (95% CrI −17.14 to −12.80), MPH ER −9.33 (−11.63 to −7.04), guanfacine ER −8.68 (−10.63 to −6.72), atomoxetine −6.88 (−8.22 to −5.49).
Funding / affiliation: Authors affiliated with Shire (guanfacine ER and lisdexamfetamine manufacturer) per PubMed record.
Joseph A, Ayyagari R, Xie M, et al. (2017). Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry 26(8):875-897. DOI · PubMed 28258319
-
ADHD medicines (class)
A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.
Class-level comparison of amphetamines and methylphenidate, not of these two products.
Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.
Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).
Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390
Switching between them (label)
What each FDA label says about starting it after another medicine. Switch the clinician view on to see the full label wording and any dose tables. More in the switching guide.
Concerta (label section 2.4, Prescribing Information, revised 04/2026): If you take short-acting methylphenidate two or three times a day, the Concerta label gives a matching once-a-morning starting dose.
Starting dose for patients switching from immediate-release methylphenidate given two or three times daily (10–60 mg/day). The 72 mg dose is only for patients 13–65 years old. Adjust in 18 mg steps at weekly intervals.
| Previous immediate-release methylphenidate | Concerta starting dose |
|---|---|
| 5 mg two or three times daily | 18 mg every morning |
| 10 mg two or three times daily | 36 mg every morning |
| 15 mg two or three times daily | 54 mg every morning |
| 20 mg two or three times daily | 72 mg every morning (ages 13–65 only) |
Vyvanse (label section 2.2, Prescribing Information, revised 04/2026): Vyvanse capsules and chewables can be swapped at the same strength.
Vyvanse capsules and chewable tablets can be substituted unit-per-unit and mg-per-mg (for example, a 30 mg capsule for a 30 mg chewable tablet).
For clinicians
Label facts are from each product’s current prescribing information (Concerta: revised 04/2026; Vyvanse: revised 04/2026). Evidence summaries show the study detail and funding; comparative statements are limited to head-to-head trials, analyses of them and network meta-analyses. Indirect comparisons (for example, matching-adjusted indirect comparisons) are not used for efficacy claims.
Talk to your prescriber. These two medicines are not interchangeable at the same dose unless a label says so. Bring this page to your appointment if it helps, but do not change, stop or swap medicines on your own.
Frequently asked questions
What is the difference between Concerta and Vyvanse?
Concerta contains methylphenidate hydrochloride (extended-release tablet (OROS)); Vyvanse contains lisdexamfetamine dimesylate (capsule or chewable tablet). Concerta: Schedule II controlled substance (CII). Vyvanse: Schedule II controlled substance (CII). The side-by-side table on this page lists approved ages, doses, duration and generic status from each label.
Is Concerta more effective than Vyvanse?
Newcorn 2017: In two adolescent trials comparing lisdexamfetamine and OROS methylphenidate directly, lisdexamfetamine was better in the fixed-dose trial but not in the flexible-dose trial. Soutullo 2013: A later analysis of that same European trial found lisdexamfetamine reduced symptoms more than OROS methylphenidate (the Concerta-type formulation). This was a post hoc comparison the trial was not designed for. Results from one study population may not apply to every patient; the best choice depends on the person.
Which lasts longer, Concerta or Vyvanse?
Per the labels: Concerta: About 10–12 hours after a morning dose; benefit lasted through 12 hours in the label’s studies in children. Vyvanse: Benefit through 12–13 hours in children and up to 14 hours in adults in label studies. These figures come from separate label studies, not from one study comparing the two.
Can you switch from Concerta to Vyvanse?
Neither label gives a milligram conversion between these two products. Concerta label: Starting dose for patients switching from immediate-release methylphenidate given two or three times daily (10–60 mg/day). The 72 mg dose is only for patients 13–65 years old. Adjust in 18 mg steps at weekly intervals. Vyvanse label: Vyvanse capsules and chewable tablets can be substituted unit-per-unit and mg-per-mg (for example, a 30 mg capsule for a 30 mg chewable tablet). Any switch is planned and adjusted by the prescriber.
Are Concerta and Vyvanse available as generics?
Concerta: Generic available. Vyvanse: Generic available. Current supply is tracked on the availability tracker page.
Sources
- Janssen Pharmaceuticals, Inc. Concerta (methylphenidate HCl) Extended-Release Tablets Prescribing Information, revised 04/2026. DailyMed (accessed Oct 2026).
- Takeda Pharmaceuticals America, Inc. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets, CII. Prescribing Information, revised 04/2026. DailyMed (accessed Oct 2026).
- Newcorn JH, Nagy P, Childress AC, et al. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2017;31(11):999-1014. PubMed
- Soutullo C, Banaschewski T, Lecendreux M, et al. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs. 2013;27(9):743-51. PubMed
- Coghill D, Banaschewski T, Lecendreux M, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23(10):1208-18. PubMed
- Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875-897. PubMed
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. PubMed